AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg), Phenytoin (300 mg), and Phenobarbital (300 mg)
Number of subjects: 0
Study 1106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg)
Number of subjects: 0
Study 1106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg)
Number of subjects: 0
Study 1106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (300 mg)
Number of subjects: 0
Study 295704 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dental health care instruction
Number of subjects: 96
Study 295704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prophylaxis
Number of subjects: 96
Study 295704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prophylaxis and dental health care instruction
Number of subjects: 96
Study 295704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 31369090 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated Fatty Acids (SFA)
Number of subjects: 61
Study 31369090 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated Fatty Acids (PUFA)
Number of subjects: 61
Study 28329340 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg enteric-coated aspirin daily for 5 years
Number of subjects: 19114
Study 28329340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 27611093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led collaborative care model (Intervention Group)
Number of subjects: 325
Study 27611093 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control Group)
Number of subjects: 325
Study 24368578 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise program (EXE; N = 6)
Number of subjects: 13
Study 22889296 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-A
Number of subjects: 408
Study 22889296 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-A and PRP-AP
Number of subjects: 408
Study 22889296 — intervention group
Group type: COMPARATOR
Intervention: PRP-AP
Number of subjects: 408
Study 22889296 — intervention group
Group type: COMPARATOR
Intervention: Control (school-as-usual)
Number of subjects: 408
Study 19517208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0
Study 17300299 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopic surgery
Number of subjects: 42
Study 15041391 — intervention group
Group type: COMPARATOR
Intervention: Muromonab (OKT 3) + Neoral + adjunct + standard prednisone
Number of subjects: 245
Study 15041391 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulect + Neoral + adjunct + steroid sparing
Number of subjects: 245
Study 15041391 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulect + Neoral + adjunct + no prednisone
Number of subjects: 245
Study 11607869 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination training in spacecurl, kinaesthetics/back protective patient transfer
Number of subjects: 0
Study 11607869 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained individuals)
Number of subjects: 0
Study 9738728 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5-mg chewable tablet) once daily in the evening for 2 days
Number of subjects: 27
Study 9738728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8281660 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (low-osmolality contrast agent)
Number of subjects: 2166
Study 8281660 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate (high-osmolality contrast agent)
Number of subjects: 2166
Study 8281660 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for selective use of low-osmolality agents
Number of subjects: 2166
Study 2973476 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 72
Study 2973476 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 72
Study 128306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sch 1000 (10 mug to 80 mug)
Number of subjects: 0
Study 128306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sch 1000 (10 to 20 mug)
Number of subjects: 0
Study 128306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sch 1000
Number of subjects: 0
Study 128306 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 0
Study 30770523 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-enhanced referral process (video orientation to CMHC and live videoconference CMHC screening visit)
Number of subjects: 342
Study 30770523 — intervention group
Group type: COMPARATOR
Intervention: Usual care procedures
Number of subjects: 342
Study 28728932 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Restriction (CR)
Number of subjects: 150
Study 28728932 — intervention group
Group type: COMPARATOR
Intervention: Simple Restriction (SR)
Number of subjects: 150
Study 26067687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (escalated from 500 mg to 1000 mg twice daily)
Number of subjects: 121
Study 26067687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 26067687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 121
Study 23941324 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week endurance training program (exercise group, n = 9)
Number of subjects: 23
Study 23941324 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (n = 6)
Number of subjects: 23
Study 21806596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle treatment
Number of subjects: 38
Study 21806596 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 38
Study 21806596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention and control groups
Number of subjects: 38
Study 19229946 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST)
Number of subjects: 60
Study 19229946 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 60
Study 16805713 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint clinical approach to treating allergic rhinitis and asthma
Number of subjects: 0
Study 16805713 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated and adjuvant treatment of rhinitis and asthma
Number of subjects: 0
Study 16805713 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical studies regarding joint treatment
Number of subjects: 0
Study 16805713 — intervention group
Group type: EXPERIMENTAL
Intervention: Future research directions
Number of subjects: 0
Study 14671052 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration (HF) with enoxaparin anticoagulation (single bolus 50 IU/kg)
Number of subjects: 10
Study 14671052 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF) with enoxaparin anticoagulation (single bolus 50 IU/kg)
Number of subjects: 10
Study 14671052 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis (HD)
Number of subjects: 10
Study 14671052 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration (HF) with enoxaparin anticoagulation (bolus of 1200 IU followed by 400 IU/h)
Number of subjects: 10
Study 14671052 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF) with enoxaparin anticoagulation (bolus of 1200 IU followed by 400 IU/h)
Number of subjects: 10
Study 14671052 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis (HD) with enoxaparin anticoagulation (bolus of 1200 IU followed by 400 IU/h)
Number of subjects: 10
Study 10921561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (200 mg)
Number of subjects: 20
Study 10921561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8609658 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (four courses of cisplatin [20 mg/m2] and fluorouracil [200 mg/m2], given daily for 5 consecutive days during weeks 1, 4, 7, and 10) plus radiotherapy (three courses of 20 Gy each, given in fractions of 2 Gy per day during weeks 2‐3, 5‐6, and 8‐9)
Number of subjects: 157
Study 8609658 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (70 Gy total dose, given in fractions of 2 Gy per day, 5 days per week)
Number of subjects: 157
Study 8609658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 157
Study 8609658 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 157
Study 1432254 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP diet with 12 modified eggs per week
Number of subjects: 98
Study 1432254 — intervention group
Group type: COMPARATOR
Intervention: NCEP diet with no whole eggs
Number of subjects: 98
Study 3906674 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg once daily)
Number of subjects: 47
Study 3906674 — intervention group
Group type: COMPARATOR
Intervention: Piretanide plus triamterene (6 mg + 50 mg once daily)
Number of subjects: 47
Study 29108532 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital versatile disc/leaflet intervention
Number of subjects: 102
Study 29108532 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 29097626 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard carbohydrate content (75 g, LCD)
Number of subjects: 82
Study 29097626 — intervention group
Group type: EXPERIMENTAL
Intervention: Double carbohydrate content (150 g, HCD)
Number of subjects: 82
Study 29097626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dataset
Number of subjects: 82
Study 29097626 — intervention group
Group type: COMPARATOR
Intervention: Insulin resistance (IR)
Number of subjects: 82
Study 25315409 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg morphine hydrochloride
Number of subjects: 39
Study 25315409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 24597251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/d for six months
Number of subjects: 52
Study 24597251 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 52
Study 21990420 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART)
Number of subjects: 118
Study 21990420 — intervention group
Group type: COMPARATOR
Intervention: Control group (80 unrelated index participants)
Number of subjects: 118
Study 18671167 — intervention group
Group type: EXPERIMENTAL
Intervention: Four types of spoken sentences presented for immediate free recall: four short simple sentences, eight short simple sentences, four compound sentences, and four random word lists.
Number of subjects: 0
Study 16756999 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 30
Study 16756999 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 14680073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.2 parts per million) for 2 hours
Number of subjects: 22
Study 14680073 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 22
Study 10622295 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg every 4 or 8 weeks)
Number of subjects: 428
Study 10622295 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg every 4 or 8 weeks)
Number of subjects: 428
Study 10622295 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 428
Study 7572705 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy restriction (84 h fasting)
Number of subjects: 5
Study 7572705 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate restriction (84 h fasting with lipid emulsion infusion for 12-15 h each day)
Number of subjects: 5
Study 1826506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with bacteriophage phi X174
Number of subjects: 11
Study 1826506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with diphtheria toxoid
Number of subjects: 11
Study 1826506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with tetanus toxoid
Number of subjects: 11
Study 1826506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with H. influenzae polyribose phosphate
Number of subjects: 11
Study 1826506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with Pneumovax
Number of subjects: 11
Study 1826506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with type 3 pneumococcal vaccine
Number of subjects: 11
Study 7006427 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 184
Study 7006427 — intervention group
Group type: EXPERIMENTAL
Intervention: Static drainage through a main wound
Number of subjects: 184
Study 7006427 — intervention group
Group type: EXPERIMENTAL
Intervention: Static drainage through a stab incision
Number of subjects: 184
Study 7006427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged drainage (static or suction)
Number of subjects: 184
Study 7006427 — intervention group
Group type: COMPARATOR
Intervention: Closed drainage
Number of subjects: 184
Study 31112610 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 449
Study 31112610 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 449
Study 31112610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 28640217 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastmilk iodine concentration (BMIC)
Number of subjects: 175
Study 28640217 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake from food
Number of subjects: 175
Study 28640217 — intervention group
Group type: EXPERIMENTAL
Intervention: Total iodine intake (food and supplements)
Number of subjects: 175
Study 28640217 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-containing supplement intake
Number of subjects: 175
Study 25651491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (lipid emulsion eye drops, omega-3 supplements, eyelid cleansing wipes)
Number of subjects: 26
Study 25651491 — intervention group
Group type: COMPARATOR
Intervention: Warm compresses
Number of subjects: 26
Study 25651491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 26
Study 25651491 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 24982065 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus fosfomycin
Number of subjects: 94
Study 24982065 — intervention group
Group type: COMPARATOR
Intervention: Colistin alone
Number of subjects: 94
Study 23014711 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 79-4980 (35 IU/kg)
Number of subjects: 139
Study 23014711 — intervention group
Group type: COMPARATOR
Intervention: rFVIII-FS (25 IU/kg)
Number of subjects: 139
Study 19283747 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17463192 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home behavioral management program (IHBMP) for 4 months
Number of subjects: 55
Study 17463192 — intervention group
Group type: COMPARATOR
Intervention: Telephone support condition (TSC) for 4 months
Number of subjects: 55
Study 17463192 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home behavioral management program (IHBMP)
Number of subjects: 55
Study 17463192 — intervention group
Group type: COMPARATOR
Intervention: Telephone support condition (TSC)
Number of subjects: 55
Study 17463192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 55
Study 15996353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone chips
Number of subjects: 33
Study 15996353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone fill material (Bio-Oss)
Number of subjects: 33
Study 15996353 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 33
Study 12365085 — intervention group
Group type: EXPERIMENTAL
Intervention: SECURUS manometer
Number of subjects: 3992
Study 12365085 — intervention group
Group type: COMPARATOR
Intervention: Aneroid or mercury sphygmomanometer
Number of subjects: 3992
Study 9834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of any oral contraceptive (OC)
Number of subjects: 821
Study 9834008 — intervention group
Group type: COMPARATOR
Intervention: Noncurrent use of oral contraceptives (OC)
Number of subjects: 821
Study 9834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Different generations of oral contraceptives
Number of subjects: 821
Study 9834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation factor VIII
Number of subjects: 821
Study 9834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Other plasmatic factors of the protein C system
Number of subjects: 821
Study 9691922 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu13‐motilin (KW‐5139) infusion at doses of 2, 4, 8, and 16 pmol/kg/min
Number of subjects: 8
Study 9691922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) infusion
Number of subjects: 8
Study 1681680 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol decanoate (ZPT‐D) 100‐600 mg every 4 weeks
Number of subjects: 64
Study 1681680 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol decanoate (HAL‐D) 38‐200 mg every 4 weeks
Number of subjects: 64
Study 7155965 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) for 14 days
Number of subjects: 33
Study 7155965 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 33
Study 30704182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine for local anesthesia (Group A)
Number of subjects: 120
Study 30704182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + midazolam + fentanyl (Group B)
Number of subjects: 120
Study 30704182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + propofol + sufentanil (Group C)
Number of subjects: 120
Study 30704182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 120
Study 28385397 — intervention group
Group type: EXPERIMENTAL
Intervention: L-proline supplementation during early pregnancy
Number of subjects: 0
Study 28385397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-proline supplementation)
Number of subjects: 0
Study 25425587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desks (SSDs) used for 4 weeks
Number of subjects: 28
Study 25425587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desks (SSDs)
Number of subjects: 28
Study 23026681 — intervention group
Group type: EXPERIMENTAL
Intervention: MVe Fitness Chair™
Number of subjects: 26
Study 23026681 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 26
Study 23026681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 26
Study 21901454 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a reaction time task with anticipation of a 'Go' signal, involving a foreperiod of 1-2 seconds, performed for 480 trials/day for 12 days.
Number of subjects: 480
Study 18054445 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing based counselling by specialized liaison service
Number of subjects: 595
Study 18054445 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing based counselling by hospital physicians
Number of subjects: 595
Study 18054445 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment as usual without additional counselling (Control)
Number of subjects: 595
Study 16493125 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 51
Study 16493125 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy (MRS)
Number of subjects: 51
Study 16493125 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) and Magnetic Resonance Spectroscopy (MRS)
Number of subjects: 51
Study 12759298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Number of subjects: 52
Study 12759298 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Number of subjects: 52
Study 10952126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0
Study 10952126 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy
Number of subjects: 0
Study 8815570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (2500 IU sc once daily for 90 days)
Number of subjects: 29
Study 8815570 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 29
Study 1945215 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (2 L of water plus usual fluid)
Number of subjects: 2
Study 1945215 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal fluid intake)
Number of subjects: 2
Study 6338842 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 152
Study 6338842 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with drainage (TV + D)
Number of subjects: 152
Study 6338842 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with antrectomy (TV + A)
Number of subjects: 152
Study 6338842 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assessment including ulcer recurrence
Number of subjects: 152
Study 29947739 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservation analysis of MSAs composed of randomly selected homologs from a PSI-BLAST search
Number of subjects: 1023
Study 29947739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial MSA sampling algorithm
Number of subjects: 1023
Study 29947739 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of Alignment by Maximal Mutual Information (SAMMI)
Number of subjects: 1023
Study 30481267 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-Gene Signature assay
Number of subjects: 202
Study 30481267 — intervention group
Group type: COMPARATOR
Intervention: Surgery only patients (control group)
Number of subjects: 202